anastrozole

(redirected from Anastrazole)
Also found in: Medical.
Related to Anastrazole: tamoxifen

anastrozole

(əˈnæstrəˌzəʊl)
n
(Pharmacology) an anti-oestrogen drug used in the treatment of breast cancer in post-menopausal women. Also called: Arimidex
Translations

anastrozole

n anastrozol m
Mentioned in ?
References in periodicals archive ?
Nancy Davidson, president of ASCO, remarked that 'many of the treatments we use, such as tamoxifen or anastrazole, not only decrease the recurrence of the known breast cancer but can also reduce the risk of developing a new second breast cancer'.
Though the pregnancy rates of 16% with anastrazole and 20% with clomiphene were similar, Dr.
Among them are the International Breast Intervention Study-2, which will randomize up to 12,000 postmenopausal women at high risk for breast cancer and 4,000 women with ductal carcinoma in situ to 5 years of anastrazole, tamoxifen, or placebo.
Generic and brand name prescription medications such as Simvastatin (generic Zocor), Fluoxetine (generic Prozac), Levothyroxine (generic Synthroid), Anastrazole (generic Armidex), as well as brand names such as Lipitor, Viagra, Lyrica, and Propecia.
This paper reports the extension of an analysis of the cost-utility of upfront anastrazole and sequential tamoxifen/exemestane compared to tamoxifen alone, which was considered from the perspective of the Canadian health system.
Ongoing studies are looking at the potenial benefits of switching patients from tamoxifen to anastrazole, said Dr.
The Ovarian Cancer Guidelines panel broadened the listing of acceptable recurrence modalities for ovarian cancer to include anastrazole (Arimidex, AstraZeneca), bevacizumab (Avastin, Genentech), irinotecan (Camptosar, Pfizer), ifosfamide (Ifex, Bristol Myers-Squibb) and letrozole (Femara, Novartis).
Ongoing studies are evaluating potential benefits of switching patients from tamoxifen to anastrazole, according to Dr.
Tenders are invited for Procurement of general drugs for the year 2014-2015 group4 Anastrazole Tab.
The Working Group indicated that the 47-month follow-up data from the ARIMIDEX early breast cancer trial (ATAC -- ARIMIDEX, Tamoxifen, Alone or in Combination) provide "a greater level of assurance, in terms of both toxicity and efficacy, for physicians and their patients who are considering the use of anastrazole (ARIMIDEX) in the adjuvant setting.
to anastrazole in suppressing estrogen levels, and a head-to-head
Braeburn is actively exploring partnership opportunities with other potential platform applications, including anastrazole (breast cancer) and rasagiline (Parkinson's).